4Sc

4Sc Current Liabilities

Delisted

The Current Liabilities of 4Sc (VSC.DE) as of Oct 12, 2026 is 851,000.00 EUR. In the previous year, Current Liabilities was 5.31 M EUR — a change of -83.96% (lower).

Current Liabilities

851,000.00EUR

YoY

-83.96%

Last updated:

Current Liabilities of 4Sc is 2022 851,000.00 EUR. Current Liabilities of 4Sc was 2021 5.31 M EUR. It decreases by -83.96% lower compared to the previous year.

The 4Sc Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2015
6.59 M EUR
Jan 1, 2016
4.19 M EUR
Jan 1, 2017
4.12 M EUR
Jan 1, 2018
2.65 M EUR
Jan 1, 2019
3.34 M EUR
Jan 1, 2020
3.86 M EUR
Jan 1, 2021
5.31 M EUR
Jan 1, 2022
851,000.00 EUR
The 4Sc Current Liabilities history
YEARCurrent LiabilitiesYoY
851,000.00EUR-83.96%
5.31 MEUR+37.36%
3.86 MEUR+15.73%
3.34 MEUR+25.88%
2.65 MEUR-35.66%
4.12 MEUR-1.72%
4.19 MEUR-36.35%
6.59 MEUR+36.02%
4.84 MEUR-0.10%
4.85 MEUR+38.53%
3.50 MEUR-0.68%
3.52 MEUR+1.79%
3.46 MEUR+19.76%
2.89 MEUR-38.86%
4.73 MEUR+45.27%
3.25 MEUR—
0.00EUR-100.00%
1.34 MEUR-59.15%
3.28 MEUR+180.34%
1.17 MEUR-38.10%
1.89 MEUR—
Access this data via the Eulerpool API
Get Free API Key

4Sc Stock analysis

What does 4Sc do? The 4Sc AG is a German biotechnology company specializing in the discovery and development of drugs for numerous indications. It was founded in 2007 and focuses on innovative immunotherapies against cancer, autoimmune diseases, and inflammation. The company's goal is to bring promising drug candidates to Phase IIb clinical trials and then license them to partner companies. Its business model involves working with academic and clinical institutions to research and expand its pipeline. The company's portfolio is divided into three main areas: oncology, autoimmune diseases, and inflammation. It develops drugs that utilize the body's immune system to target cancer cells, inhibit inflammation for autoimmune diseases, and specifically target inflammation for other conditions. Overall, 4Sc AG aims to discover and develop novel drugs that can help patients with severe medical conditions. 4Sc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 4Sc stock

Current Liabilities of 4Sc is 851,000.00 EUR in 2022.

Current Liabilities of 4Sc changed from 5.31 M EUR to 851,000.00 EUR, representing a -83.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities 4Sc since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's 4Sc historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — 4Sc

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — 4Sc